Opinion: In the search for Alzheimer’s drugs, researchers must look beyond beta amyloid
In the search for Alzheimer's drugs, it's time to pay more attention to drugs that go beyond targeting beta amyloid, a protein linked to the disease.
As I read the findings about drugs targeting beta amyloid proteins that were released during the annual Clinical Trials in Alzheimer’s Disease conference in Boston earlier this month, I thought of a favorite old quote, “99 percent of success is built on failure.” But that only holds true if we are learning from our mistakes.
Trials of drugs targeting beta amyloid — which makes up the plaques common
